Recent Quotes (30 days)

You have no recent quotes
chg | %

DiagnoCure Inc.  

(Public, TSE:CUR)   Watch this stock  
Find more results for CUR
0.000 (0.00%)
Oct 2 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 0.10 - 0.10
52 week 0.09 - 0.25
Open 0.10
Vol / Avg. 14,400.00/13,782.00
Mkt cap 4.30M
P/E     -
Div/yield     -
EPS -0.04
Shares 43.04M
Beta -0.17
Inst. own     -
Sep 11, 2015
Q3 2015 Diagnocure Inc Earnings Release

Key stats and ratios

Q3 (Jul '15) 2014
Net profit margin -206.27% -367.38%
Operating margin -212.29% -377.64%
EBITD margin - -316.82%
Return on average assets -24.36% -30.37%
Return on average equity - -1213.84%
Employees 10 -
CDP Score - -


4535 boul. Wilfrid-Hamel Ouest,, Bureau 250
+1-418-5276100 (Phone)
+1-418-5270240 (Fax)

Website links


DiagnoCure Inc. is a Canada-based biotechnology company. The Company is engaged in the development and commercialization of products indicated for the diagnosis of cancer. The Company develops and provides molecular and genomic tests to support effective clinical decisions enabling personalized medicine in oncology. The Company’s prostate cancer marker PROGENSA PCA3 is a tool for the diagnosis and management of prostate cancer patients. The Company’s products also include Previstage GCC colorectal cancer staging test, which uses Guanylyl Cyclase C (GCC or GUCY2C) marker to stratify the risk of colon cancer recurrence by determining the stage of the disease. The Company’s subsidiaries include Catalyst Oncology LP, 9184‐6766 Quebec Inc. and 9161‐6722 Quebec Inc.

Officers and directors

Yves Fradet M.D. Chairman of the Board, President, Chief Medical Officer
Frederic Boivin Senior Director - Finance and Administration
Vincent R. Zurawski Jr., Ph.D. Non Executive Lead Independent Director
Andrew J. Sheldon Independent Director
Jacques Simoneau PH.D. Independent Director
Age: 57
Louise Proulx Ph.D. Non-Executive Independent Director